Danaher Corporation DHR

Danaher Corporation (Danaher) diseña, fabrica y comercializa productos y servicios profesionales, médicos, industriales y comerciales. La empresa opera a través de tres segmentos: Ciencias de la Vida, Diagnóstico y Soluciones Ambientales y Aplicadas. El segmento de Ciencias de la Vida ofrece una variedad de instrumentos y consumibles que son utilizados principalmente por los clientes para estudiar los bloques básicos de la vida, incluyendo genes, proteínas, metabolitos y células, para comprender las causas de las enfermedades, identificar nuevas terapias, y probar y fabricar nuevos medicamentos y vacunas. El segmento de Diagnóstico ofrece instrumentos clínicos, reactivos, consumibles, software y servicios que hospitales, consultorios médicos, laboratorios de referencia y otros entornos de atención crítica utilizan para diagnosticar enfermedades y tomar decisiones de tratamiento. El segmento de Soluciones Ambientales y Aplicadas ofrece productos y servicios que ayudan a proteger recursos preciosos y mantener seguros los suministros globales de alimentos y agua.

Con 5 acciones de DHR (USD 1.104,25) habrías recibido USD 7,60 en dividendos en los últimos 12 meses.

DHR separó parte de su negocio en una nueva empresa (spin-off) el 5 de julio de 2016. Sus accionistas recibieron acciones de la nueva compañía, y por eso el precio histórico de DHR está ajustado.

• GlobeNewswire Inc. 5 oct

  Europe Point of Care Diagnostics Market Size and Forecast, 2021 - 2031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR

  Europe's Point of Care (POC) Diagnostics Market is projected to grow from US$8.9 billion in 2024 to US$21.4 billion by 2031, with a 13.4% CAGR driven by rapid testing innovation, molecular diagnostics advancement, and increasing prevalence of infectious and chronic diseases. Germany leads the regional market, supported by strong healthcare infrastructure and public health initiatives. Key players include Siemens AG, Abbott Laboratories, Roche, bioMerieux, Bio-Rad, QIAGEN, Nova Biomedical, Polymer Technology Systems, and Danaher Corp.

  

• GlobeNewswire Inc. 5 oct

  Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion Opportunity

  The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.

  

• GlobeNewswire Inc. 5 oct

  Cell and Gene Therapy Biomanufacturing Market - Size, Share, and Forecast, 2026-2031 | Automation, Viral Vectors, and CDMO Expansion Drive 11.7% CAGR to $8.7 Billion

  The global cell and gene therapy biomanufacturing market is projected to grow from $5.0 billion in 2026 to $8.7 billion by 2031, driven by an 11.7% CAGR. Growth is fueled by increasing regulatory approvals, rising demand for scalable manufacturing infrastructure, and investments in automation and modular systems. However, high production costs, regulatory complexity, and workforce shortages remain significant challenges.

  

• GlobeNewswire Inc. 5 oct

  Magnetic Beads Market - Global Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion

  The global magnetic beads market is projected to grow from USD 3.90 billion in 2026 to USD 6.18 billion by 2032, driven by automation, molecular diagnostics, genomics, and bioprocessing applications. Key growth drivers include adoption of automated magnetic separation platforms, advanced surface chemistries, AI-enabled workflow optimization, and expanding diagnostics capacity across regions. Strategic priorities for industry leaders include developing application-specific chemistries, strengthening supply-chain resilience, and leveraging AI analytics.

  

• Zacks Investment Research 2 oct

  Parker-Hannifin Benefits From Business Strength Amid Headwinds

  Parker-Hannifin reported strong momentum in its Aerospace Systems segment with 13.3% organic sales growth and 18% order increases in fiscal Q4 2026. The company completed the acquisition of Filtration Group and has a pending deal for CIRCOR's aerospace business. However, rising operating expenses, $6.77 billion in long-term debt, and $401 million in annual interest expenses pose challenges to profitability.